{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:50:39Z","timestamp":1788929439790,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Internal Grant Agency of the Ministry of Health of the Czech Republic","award":["NT\/12171-5"],"award-info":[{"award-number":["NT\/12171-5"]}]},{"name":"Grant Agency of the Charles University","award":["411911"],"award-info":[{"award-number":["411911"]}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["15-07544S"],"award-info":[{"award-number":["15-07544S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["303\/12\/1162"],"award-info":[{"award-number":["303\/12\/1162"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"USPHS NIH","award":["DK38226"],"award-info":[{"award-number":["DK38226"]}]},{"DOI":"10.13039\/100000928","name":"Robert A. Welch Foundation","doi-asserted-by":"crossref","award":["GL625910"],"award-info":[{"award-number":["GL625910"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.vph.2015.08.013","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T22:44:57Z","timestamp":1440197097000},"page":"45-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats"],"prefix":"10.1016","volume":"73","author":[{"given":"Petra","family":"Al\u00e1nov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Huskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Kopkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sporkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160\u00e1rka","family":"J\u00edchov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Neck\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Imig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Klevstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Kol\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rami Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Falck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert J.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Melenovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"\u010cervenkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kujal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Vernerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"\u010cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.08.013_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1074248413499973","article-title":"Pharmacologic therapy that simulates conditioning for cardiac ischemic\/reperfusion injury","volume":"19","author":"Sivaraman","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.vph.2015.08.013_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia\u2013reperfusion injury: a neglected therapeutic target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2015.08.013_bb0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2011.07.054","article-title":"An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials","volume":"59","author":"Gerczuk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0020","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"31","author":"ESH\/ESC Task Force for the Management of Arterial Hypertension","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/pr.107.06002","article-title":"Interaction of cardiovascular risk with myocardial ischemia\/reperfusion injury, preconditioning, and postconditioning","volume":"59","author":"Ferdinandy","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vph.2015.08.013_bb0030","first-page":"180","article-title":"Mechanisms of load dependency of myocardial ischemia reperfusion injury","volume":"3","author":"Mozaffari","year":"2013","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.vph.2015.08.013_bb0035","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/pr.113.008300","article-title":"Interaction of risk factors, comorbidities, and comedications with ischemia\/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning","volume":"66","author":"Ferdinandy","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vph.2015.08.013_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.00021.2011","article-title":"Epoxides and soluble epoxide hydrolase in cardiovascular physiology","volume":"92","author":"Imig","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vph.2015.08.013_bb0045","first-page":"R321","article-title":"Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease","volume":"302","author":"Elmarakby","year":"2012","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0050","first-page":"R1468","article-title":"Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats","volume":"300","author":"Sporkov\u00e1","year":"2011","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-I-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"122","author":"Neck\u00e1\u0159","year":"2012","journal-title":"Clin Sci"},{"key":"10.1016\/j.vph.2015.08.013_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1113\/jphysiol.2010.199505","article-title":"Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension","volume":"589","author":"Honetschl\u00e4gerov\u00e1","year":"2011","journal-title":"J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000339883","article-title":"Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension","volume":"35","author":"Kopkan","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/1440-1681.12018","article-title":"Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin\u2013angiotensin system","volume":"40","author":"Varcabov\u00e1","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0075","first-page":"H2838","article-title":"Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart","volume":"294","author":"Gross","year":"2008","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/FJC.0b013e3181c37d69","article-title":"Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamntan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury","volume":"55","author":"Chaudhary","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2015.08.013_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/FJC.0b013e31827afcee","article-title":"Effects of ischemia reperfusion injury and epoxyeicosatrienoic acids on caveolin expression in mouse myocardium","volume":"61","author":"Chaudhary","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2015.08.013_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yjmcc.2013.02.003","article-title":"Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts","volume":"59","author":"Gross","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0095","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/HJH.0b013e328349062f","article-title":"Inhibition of soluble epoxide hydrolase improves the impaired pressure\u2013natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats","volume":"29","author":"Honetschl\u00e4gerov\u00e1","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HJH.0b013e32835b50aa","article-title":"Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME","volume":"31","author":"Honetschl\u00e4gerov\u00e1","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.05.016","article-title":"Epoxyeicosatrienoic acids and cardioprotection: the road to translation","volume":"74","author":"Oni-Orisan","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0110","article-title":"Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism","author":"Spector","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vph.2015.08.013_bb0115","first-page":"H337","article-title":"Comparison of vasodialatory properties of 14,15-EETs analogs: structural requirements for dilatation","volume":"284","author":"Falck","year":"2003","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0120","article-title":"14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition","volume":"5069\u20135075","author":"Falck","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.vph.2015.08.013_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fphys.2010.00157","article-title":"Development of epoxyeiocastrienoic acids analogs with in vivo anti-hypertensive actions","volume":"1","author":"Imig","year":"2010","journal-title":"Front Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.113.01949","article-title":"Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat","volume":"62","author":"Khan","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/CS20130479","article-title":"Epoxyeicosatrienoic acid (EET) analog lowers blood pressure through vasodilatation and sodium channel inhibition","volume":"127","author":"Khan","year":"2014","journal-title":"Clin Sci"},{"key":"10.1016\/j.vph.2015.08.013_bb0140","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00004872-200105000-00020","article-title":"Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonamide analog of 11,12-epoxyeicosatrienoic acid","volume":"19","author":"Imig","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0145","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1046\/j.1523-1755.2003.00036.x","article-title":"Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles","volume":"63","author":"Wang","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.vph.2015.08.013_bb0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-201X.2000.00638.x","article-title":"Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole","volume":"168","author":"Kohagure","year":"2000","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.vph.2015.08.013_bb0155","first-page":"R60","article-title":"20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II","volume":"283","author":"Alonso-Galicia","year":"2002","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0160","first-page":"R977","article-title":"Increased renal vascular reactivity to angiotensin II after unilateral nephrectomy in the rat involves 20-HETE","volume":"291","author":"Joly","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/HJH.0b013e328334dfd4","article-title":"Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats","volume":"28","author":"Walkowska","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0170","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/HYPERTENSIONAHA.107.105395","article-title":"Altered release of cytochrome P450 metabolites of arachidonic acid in renovascular disease","volume":"51","author":"Minuz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0175","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1042\/BST0380841","article-title":"A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection","volume":"38","author":"Halestrap","year":"2010","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.vph.2015.08.013_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yjmcc.2012.04.008","article-title":"Role of PI3K\u03b1 and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection","volume":"53","author":"Batchu","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/01.HYP.0000150857.39919.cb","article-title":"Recommendations for blood pressure measurements in humans and experimental animals. Part 2: blood pressure measurements in experimental animals","volume":"45","author":"Kurtz","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0190","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1097\/HJH.0b013e32832f0d06","article-title":"Impairment of angiotensin-converting 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension","volume":"27","author":"B\u00fcrgelov\u00e1","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2015.08.013_bb0195","doi-asserted-by":"crossref","first-page":"29-41","DOI":"10.1042\/CS20100527","article-title":"Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats","volume":"121","author":"Benes","year":"2011","journal-title":"Clin Sci"},{"key":"10.1016\/j.vph.2015.08.013_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.12419","article-title":"Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula","author":"\u010cervenka","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0205","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00428-003-0775-5","article-title":"Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension","volume":"442","author":"Buzello","year":"2003","journal-title":"Virchows Arch"},{"key":"10.1016\/j.vph.2015.08.013_bb0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2613.2007.00546.x","article-title":"Cardiac and aortic structural alterations due to surgically-induced menopause associated with renovascular hypertension in rats","volume":"88","author":"Mendoca de","year":"2007","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.vph.2015.08.013_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.33549\/physiolres.932861","article-title":"Intrapulmonary activation of the angiotensin-converting enzyme type 2\/angiotensin 1-7\/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia","volume":"64","author":"Hampl","year":"2015","journal-title":"Physiol Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0220","first-page":"597","article-title":"Effects of adaptation to intermittent high altitude hypoxia on ischemic ventricular arrhythmias in rats","volume":"49","author":"Asemu","year":"2002","journal-title":"Physiol Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0225","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/01.HYP.0000036452.28493.74","article-title":"Essential role of AT1A receptor in the development of 2K1C hypertension","volume":"40","author":"\u010cervenka","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0230","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000339883","article-title":"Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension","volume":"35","author":"Kopkan","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0235","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bph.12960","article-title":"Cardiac NO signaling in the metabolic syndrome","volume":"172","author":"Pech\u00e1\u0148ov\u00e1","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2015.08.013_bb0240","doi-asserted-by":"crossref","DOI":"10.33549\/physiolres.932939","article-title":"Role of NO\/cGMP signaling pathway in cardiac ischemic tolerance of chronically hypoxic rats","author":"Al\u00e1nov\u00e1","year":"2015","journal-title":"Physiol Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0002-9149(72)90454-7","article-title":"Ischemic contracture of the heart: \u201cstone heart\u201d","volume":"29","author":"Cooley","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0250","first-page":"152","article-title":"Transmural progression of morphological changes during ischemia and reperfusion in the normal and hypertrophied heart","volume":"129","author":"Anderson","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vph.2015.08.013_bb0255","first-page":"395","article-title":"Recovery of healthy and hypertrophied hearts after global ischemia and gradual reperfusion","volume":"43","author":"Minor","year":"1994","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cvr\/20.1.67","article-title":"Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischaemia","volume":"20","author":"Snoeckx","year":"1986","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0265","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.HYP.0000095614.91961.40","article-title":"Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury","volume":"42","author":"Mozaffari","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0270","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/01.HYP.35.5.1167","article-title":"Comparison of hearts with 2 types of pressure-overload left ventricular hypertrophy","volume":"35","author":"Saupe","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0b013e3182760c4d","article-title":"Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats","volume":"61","author":"Wagner","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2015.08.013_bb0280","first-page":"H2473","article-title":"Angiotensin II type 1 receptor blocker preserves tolerance to ischemia\u2013reperfusion injury in Dahl salt-sensitive rat heart","volume":"294","author":"Matsuhisa","year":"2008","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0285","first-page":"437","article-title":"Myocardial susceptibility to ischemic damage: a comparative study of disease models in the rat","volume":"7","author":"Hearse","year":"1978","journal-title":"Eur J Cardiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0290","series-title":"The Kidney: Physiology and Pathophysiology","first-page":"1009","article-title":"The renin\u2013angiotensin\u2013aldosterone system: renal mechanisms and circulatory homeostasis","author":"Hall","year":"2000"},{"key":"10.1016\/j.vph.2015.08.013_bb0295","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1755-5922.2009.00108.x","article-title":"Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia\u2013reperfusion model","volume":"28","author":"Dai","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.vph.2015.08.013_bb0300","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin\u2013angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.vph.2015.08.013_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/phy2.151","article-title":"Cardioprotective effects of angiotensin III against ischemic injury via the AT2 receptor and KATP channels","author":"Park","year":"2013","journal-title":"Physiol Rep"},{"key":"10.1016\/j.vph.2015.08.013_bb0310","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/HYPERTENSIONAHA.113.02902","article-title":"Aliskiren reduces myocardial ischemia\u2013reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism","volume":"63","author":"Koid","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.08.013_bb0315","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FJC.0b013e31821324b6","article-title":"Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester","volume":"57","author":"Benter","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2015.08.013_bb0320","first-page":"H500","article-title":"Effects of selective inhibition of cytochrome P-450 \u03c9-hydroxylases and ischemic preconditioning in myocardial protection","volume":"290","author":"Nithipatikom","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2006.10.004","article-title":"Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy","volume":"55","author":"Ebrahim","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0330","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/cvr\/28.7.1025","article-title":"Ischaemic preconditioning protects hypertrophied myocardium","volume":"28","author":"Speechly-Dick","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2015.08.013_bb0335","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2015.08.013_bb0340","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1440-1681.12204","article-title":"Inhibition of soluble epoxide hydrolase is renoprotective in 5\/6 nephrectomized Ren-2 transgenic rats","volume":"41","author":"Kujal","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0345","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/01.ASN.0000130154.42061.C6","article-title":"Increased infarct size in uremic rats: reduced ischemia tolerance?","volume":"15","author":"Dikow","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.vph.2015.08.013_bb0350","first-page":"H1229","article-title":"Preconditioning protects the heart in a prolonged uremic condition","volume":"303","author":"Kocsis","year":"2012","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.08.013_bb0355","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.105.091140","article-title":"Hyperlipidemia attenuates the infarct size-limiting effect of preconditioning: role of matrix metalloproteinase-2 inhibition","volume":"16","author":"Giricz","year":"2006","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T08:28:56Z","timestamp":1599467336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":71,"alternative-id":["S1537189115001998"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.08.013","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}